Insider Transactions in Q4 2024 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,759
-2.36%
|
$26,313
$7.84 P/Share
|
|
Dec 16
2024
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+4.98%
|
-
|
|
Dec 02
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,982
-3.07%
|
$17,838
$9.07 P/Share
|
|
Dec 02
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+5.7%
|
-
|
|
Dec 02
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,784
-3.01%
|
$16,056
$9.07 P/Share
|
|
Dec 02
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,516
+5.6%
|
-
|
|
Dec 02
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,426
-2.06%
|
$39,834
$9.07 P/Share
|
|
Dec 02
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+4.63%
|
-
|
|
Nov 12
2024
|
Ryan D Maynard Director |
SELL
Open market or private sale
|
Direct |
50,000
-86.96%
|
$500,000
$10.06 P/Share
|
|
Nov 12
2024
|
Ryan D Maynard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+46.51%
|
$350,000
$7.45 P/Share
|
|
Oct 14
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-2.5%
|
$12,852
$9.77 P/Share
|
|
Oct 14
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+4.68%
|
-
|
|
Oct 14
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-2.3%
|
$12,852
$9.77 P/Share
|
|
Oct 14
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+4.33%
|
-
|
|
Oct 14
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-4.15%
|
$79,659
$9.77 P/Share
|
|
Oct 14
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+8.91%
|
-
|